Arvinas Inc Sustainability Reports
Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company utilizes its proprietary PROTAC protein degradation platform to target debilitating and life-threatening diseases.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00LW7YL08
8 reports from 2018 to 2025
Company Profile
Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company utilizes its proprietary PROTAC protein degradation platform to target debilitating and life-threatening diseases.
Reports
8 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
